Malaria Clinical Trial
Official title:
Computerized Cognitive Rehabilitation in Children After Severe Malaria
Brain training exercises will be provided to children who survived an episode of severe malaria. These children will be given assessments for cognition, behaviour and executive functions before and after the brain training exercises.
Background:
Our Fogarty "Brain Disorders" R21 study findings demonstrated that attention and working
memory deficits persist in one out of four children with cerebral malaria (CM) (Boivin et
al., 2007; John, Bangirana et al., 2008). Uganda has one of the highest incidences of
malaria worldwide (~480/1000) with about 10% of these incidents becoming severe and over 90%
of such cases occurring in children (Snow, Guerra, Noor, Myint, & Hay, 2005). This results
in an estimated 80 thousand new cases each year of Ugandan children with mild to severe
neurocognitive impairment from this disease. Such impairment will likely compromise their
school performance, impede their activities of daily living, and lessen their future
economic opportunities.
There is no known treatment intervention during acute illness to prevent CM brain-injury
effects (Abubakar et al., 2007). Nor are neurocognitive rehabilitative treatment programs
available in low-resource settings for affected children. However, we have successfully
piloted a computerized cognitive rehabilitation therapy (CCRT) intervention to specifically
improve attention, visual-spatial learning, and psychosocial adjustment (domains shown most
affected by CM in our previous studies) with school-age Ugandan CM survivors (Bangirana,
Giordani et al., 2009). This evidence justifies an R01 for further study.
The present application proposes a randomized control trial (RCT) to further establish that
CCRT can improve attention, working memory, aspects of executive functioning, and
psychosocial adjustment in pediatric CM survivors. Such programs are already being used
extensively with children with developmental disabilities (e.g., Attention Deficit
Hyperactivity Disorder, learning disorders) and brain injury in high-income countries. The
evidence from RCT studies for these interventions is strong enough to warrant the evaluation
of CCRT for at-risk African children (Bangirana, Idro, John, & Boivin, 2006; Boivin &
Giordani, 2009). CCRT could also then be extended to a variety of other infectious diseases
causing brain injury and persisting neurocognitive deficits to children in this setting
(e.g., HIV, schistosomiasis, meningitis, encephalitis, and neurocysticercosis).
Objectives:
1. To evaluate the effectiveness of CCRT in improving neuropsychological performance and
psychiatric outcomes in Ugandan children who survive severe malaria.
2. To evaluate whether severity of malaria illness (e.g., immunological brain
inflammation, EEG abnormalities) is predictive of neuropsychological benefit from CCRT.
3. METHODS
Study design:
Randomized controlled trial
Study Population:
Our proposed study groups of children aged 5 to 12 years will consist of 150 children with
severe malaria (either cerebral malaria or severe malaria anemia). From the homes of these
severe malaria children, we will also recruit 1 sibling (or neighbor child) 5 to 12 years of
age without a history of cerebral malaria or other known infectious disease that could cause
brain injury (Community Controls from Home: CC children N = 150).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |